banter and General Discussion, page-7870

I love the sheer volume of developments a simple google search brings up now for stem cells. 4 overnight developments on northern hemisphere time. It might have been 1 or 2 at best pre-COVID. The pace for developments has noticeably picked up and the FDA can no longer deny the noise....:



Even the Aussie government picking up on the advancements and possibilities ($150 million investment):

https://www.health.gov.au/our-work/mrff-stem-cell-therapies-mission

Capital investments getting announced near weekly now:

https://www.investing.com/news/stock-market-news/earnings-call-biolinerx-announces-fda-approval-of-stem-cell-mobilization-drug-motixafortide-93CH-3239578

"Additionally, BioLineRx has closed an exclusive license agreement with Gloria Biosciences for the development and commercialization of Motixafortide in Asia. This agreement includes an upfront payment of $15 million, with potential milestone and royalty payments totaling up to $250 million. This partnership is significant considering Asia reported over 51,000 cases of multiple myeloma in 2022, marking it as a substantial market."

(Motixafortide in autologous hematopoietic stem cell-based gene therapy for sickle cell disease)